Neurocrine Biosciences
NBIX
133 hedge funds and large institutions have $1.68B invested in Neurocrine Biosciences in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 46 reducing their positions, and 22 closing their positions.
14% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 22
0% more funds holding
Funds holding: 133 → 133 (0)
4% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 46
11% less capital invested
Capital invested by funds: $1.88B → $1.68B (-$199M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
67% less call options, than puts
Call options by funds: $17.4M | Put options by funds: $52.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$16.7M |
| 2 |
Millennium Management
New York
|
+$16.7M |
| 3 |
PC
PointState Capital
New York
|
+$14.2M |
| 4 |
VAM
Visium Asset Management
New York
|
+$12.8M |
| 5 |
CCI
Columbus Circle Investors
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Americafirst Capital Management
Roseville,
California
|
-$734M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$22M |
| 3 |
PA
Perceptive Advisors
New York
|
-$18.9M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$10.6M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$5.34M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QT
151
Quantbot Technologies
New York
| – | -$70K | -4,469 | Closed |
|
|
PCM
152
Prelude Capital Management
New York
| – | -$47.4K | -2,500 | Closed |
|
|
PTC
153
Private Trust Company
Cleveland,
Ohio
| – | -$10K | -631 | Closed |
|
|
NFG
154
Next Financial Group
Houston,
Texas
| – | -$7K | -430 | Closed |
|
155
Ameriprise
Minneapolis,
Minnesota
| – | -$6K | -385 | Closed |
|
156
Envestnet Asset Management
Chicago,
Illinois
| – | -$1K | -35 | Closed |
|
NBIX Hedge Fund Activity: Q4 2014 in Review
133 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2014, worth a combined $1.68B — down 11% from $1.88B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new NBIX positions and 22 closed out — a net gain of 3 holders — while 44 added to existing stakes and 46 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $16.7M. The largest seller was Americafirst Capital Management, exiting entirely with an estimated $734M sold.
- 133 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $1.68B of Neurocrine Biosciences stock for Q4 2014, down 11% quarter-over-quarter.
- 25 funds opened new Neurocrine Biosciences positions in Q4 2014 and 22 closed out, a net change of +3 holders.
- The largest Neurocrine Biosciences buyer in Q4 2014 was Jennison Associates, an estimated $16.7M added.
- The largest Neurocrine Biosciences seller in Q4 2014 was Americafirst Capital Management, an estimated $734M sold.
Based on aggregated 13F filings for Q4 2014.